查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1602195

旅行疫苗市場：按類型、疾病分類 - 全球預測 2025-2030

Travel Vaccines Market by Type (Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines), Disease (DPT, Hepatitis A, Hepatitis B) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年旅行疫苗市值為82.6億美元，預計2024年將達到90.9億美元，複合年成長率為10.06%，到2030年將達到161.8億美元。

旅行疫苗，也稱為旅行免疫接種，對於確保前往感染疾病流行地區的個人的健康安全至關重要。旅行疫苗的需求源於其在預防旅行者感染特定地區流行的疾病（如黃熱病、甲型肝炎和傷寒）方面的作用。其應用主要針對國際旅行的個人，在個人旅行者、商務旅行者、軍事人員和外籍人士等領域找到最終用途。

主要市場統計
基準年[2023] 82.6億美元
預測年份 [2024] 90.9億美元
預測年份 [2030] 161.8億美元
複合年成長率（%） 10.06%

影響該市場成長的關鍵因素是全球化、旅遊業和業務擴張導致國際旅行頻率的增加。此外，人們對健康風險的認知不斷提高以及衛生當局的嚴格監管也推動了市場的發展。疫苗開發方面的技術進步，例如聯合疫苗的推出，正在提供更多的商機。為了獲利，鼓勵公司投資開發具有持久保護作用和副作用較少的疫苗。此外，傳播旅行疫苗訊息的數位平台有可能擴大市場範圍。

然而，市場開拓也面臨挑戰，包括開發新疫苗的成本高昂以及延遲市場進入的監管障礙。公眾對疫苗接種的抵制和錯誤訊息也可能阻礙市場成長。此外，供應鏈中斷（例如全球健康危機期間出現的供應鏈中斷）也可能會阻礙供應。

需要創新的領域包括針對新出現疾病的疫苗的研究和開發、基於旅行者檔案的個人化疫苗接種計劃以及增強的疫苗輸送機制（例如微針貼片）。市場是動態的，受到地緣政治和環境變化的影響，需要市場相關人員保持警惕和適應，以應對新出現的健康威脅。為了有效克服這些挑戰並抓住機遇，市場相關人員必須專注於與衛生機構的合作，利用資料分析進行市場預測，並加強傳播策略。

市場動態：揭示快速發展的旅遊疫苗市場的關鍵市場洞察

供需的動態交互作用正在改變旅行疫苗市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，並了解消費行為及其對製造成本的影響，並更清楚地了解對採購趨勢的影響。

  • 市場促進因素
    • 國際觀光日益普及
    • 感染疾病的蔓延與聯合疫苗的開發
    • 低溫運輸倉儲基礎設施的最新投資和改進
  • 市場限制因素
    • 旅行者缺乏意識
  • 市場機會
    • 疫苗新技術的創新與進展
    • 政府/組織的免疫和疫苗開發資助和舉措
  • 市場挑戰
    • 疫苗處理和儲存問題

波特的五力戰略工具駕馭旅遊疫苗市場

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解旅行疫苗市場的外部影響

外部宏觀環境因素在塑造旅行疫苗市場的表現動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並幫助他們做出積極主動的決策。

市場佔有率分析 了解旅行疫苗市場的競爭格局

對旅行疫苗市場的詳細市場佔有率分析可以對供應商的業績進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，以應對日益激烈的競爭。

FPNV 定位矩陣旅遊疫苗市場供應商的績效評估

FPNV 定位矩陣是評估旅遊疫苗市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。四個象限清楚且準確地分類供應商，幫助使用者辨識最能滿足其策略目標的合作夥伴和解決方案。

本報告提供了涵蓋關鍵重點領域的全面市場分析：

1. 市場滲透率：對當前市場環境的詳細回顧，包括行業主要企業的大量資料。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監管核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 國際觀光日益普及
      • 感染疾病的傳播和聯合疫苗的開發
      • 低溫運輸倉儲基礎設施的最新投資和改進
    • 抑制因素
      • 旅客認知度低
    • 機會
      • 新疫苗技術的創新與進步
      • 政府和組織為免疫和疫苗開發提供的資金和努力
    • 任務
      • 疫苗處理和儲存問題
  • 市場區隔分析
    • 類型：引發免疫反應的 DNA 疫苗的進展
    • 疾病：根據旅行者對肝炎疫苗的需求優先考慮
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境
  • 客戶客製化

第6章 旅行疫苗市場：依類型

  • 減毒疫苗
  • 結合疫苗
  • DNA疫苗
  • 惰性疫苗
  • 重組載體疫苗
  • 次單位疫苗
  • 類毒素疫苗

第7章 旅行疫苗市場：依疾病分類

  • 二氧化矽
  • 甲型肝炎
  • B型肝炎
  • 日本腦炎
  • 麻疹和腮腺炎
  • 腦膜炎奈瑟菌
  • 狂犬病
  • 傷寒
  • 水痘
  • 黃熱病

第8章美洲旅行疫苗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太旅行疫苗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章 歐洲、中東和非洲旅行疫苗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • 印度首個本土甲型肝炎疫苗在海德拉巴上市
    • FDA 已核准PENBRAYA，這是第一個也是唯一一個用於預防導致青少年病菌感染的五種最常見血清群的疫苗。
    • 輝瑞和 BioNTech 獲得美國FDA核准2023-2024 年 COVID-19 疫苗

公司名單

  • Merck & Co., Inc.
  • Takeda Pharmaceutical Company Limited
  • Cadila Pharmaceuticals Limited
  • Shenzhen Kangtai Biological Products Co., Ltd.
  • Novartis AG
  • Dynavax Technologies Corporation
  • CSL Limited
  • Emergent BioSolutions Inc.
  • Bio-Med（P）Limited
  • Bharat Biotech Ltd.
  • Indian Immunologicals Ltd.
  • Dano Vaccines & Biologicals Private Limited
  • Bavarian Nordic A/S
  • Johnson & Johnson Services, Inc
  • Pfizer Inc.
  • Incepta Pharmaceuticals Ltd.
  • GlaxoSmithKline PLC
  • Serum Institute of India Pvt. Ltd.
  • Abbott Laboratories
  • AstraZeneca PLC
  • Walvax Biotechnology Co., Ltd.
  • Bio-Manguinhos
  • Valneva SE
  • Sanofi SA
  • Biological E Limited
Product Code: MRR-0316851957A3

The Travel Vaccines Market was valued at USD 8.26 billion in 2023, expected to reach USD 9.09 billion in 2024, and is projected to grow at a CAGR of 10.06%, to USD 16.18 billion by 2030.

Travel vaccines, also known as travel immunizations, are crucial for ensuring the health safety of individuals traveling to regions with prevalent infectious diseases. The necessity of travel vaccines stems from their role in preventing travelers from contracting diseases such as yellow fever, hepatitis A, and typhoid, which are prevalent in certain geographical areas. Their application is primarily focused on individuals who travel internationally, and they find end-use across segments such as individual tourists, business travelers, military personnel, and expatriates.

KEY MARKET STATISTICS
Base Year [2023] USD 8.26 billion
Estimated Year [2024] USD 9.09 billion
Forecast Year [2030] USD 16.18 billion
CAGR (%) 10.06%

A significant factor influencing the growth of this market is the increasing international travel frequency, driven by globalization, tourism, and business expansion. Additionally, heightened awareness of health risks and stringent regulations by health authorities also propel the market forward. Technological advancements in vaccine development, such as the introduction of combination vaccines, present further opportunities. For businesses to capitalize, investing in the development of vaccines with longer-lasting protection and fewer side effects is recommended. Moreover, digital platforms for disseminating travel vaccine information can expand market reach.

However, the market is faced with challenges, such as the high cost of developing new vaccines and regulatory hurdles that can delay market entry. Public resistance to vaccination and misinformation can also hinder market growth. Furthermore, supply chain disruptions, as observed during global health crises, can impede availability.

Areas ripe for innovation include the research and development of vaccines against emerging diseases, personalized vaccine schedules based on traveler profiles, and enhanced vaccine delivery mechanisms, such as micro-needle patches. The market is dynamic, influenced by geopolitical and environmental changes, which necessitate vigilance and adaptability from market players to address emerging health threats. To effectively navigate these challenges and seize opportunities, market players must focus on collaboration with health organizations, leverage data analytics for market forecasting, and maintain robust communication strategies to counter misinformation.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Travel Vaccines Market

The Travel Vaccines Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing Popularity of International Tourism
    • Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
    • Recent Investments and Improvement in Cold Chain Storage Infrastructure
  • Market Restraints
    • Limited Awareness Amongst Travelers
  • Market Opportunities
    • Innovations in Novel Vaccine Technologies and Advancements
    • Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
  • Market Challenges
    • Issues Related to Vaccine Handling and Storage

Porter's Five Forces: A Strategic Tool for Navigating the Travel Vaccines Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Travel Vaccines Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Travel Vaccines Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Travel Vaccines Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Travel Vaccines Market

A detailed market share analysis in the Travel Vaccines Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Travel Vaccines Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Travel Vaccines Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Travel Vaccines Market, highlighting leading vendors and their innovative profiles. These include Merck & Co., Inc., Takeda Pharmaceutical Company Limited, Cadila Pharmaceuticals Limited, Shenzhen Kangtai Biological Products Co., Ltd., Novartis AG, Dynavax Technologies Corporation, CSL Limited, Emergent BioSolutions Inc., Bio-Med (P) Limited, Bharat Biotech Ltd., Indian Immunologicals Ltd., Dano Vaccines & Biologicals Private Limited, Bavarian Nordic A/S, Johnson & Johnson Services, Inc, Pfizer Inc., Incepta Pharmaceuticals Ltd., GlaxoSmithKline PLC, Serum Institute of India Pvt. Ltd., Abbott Laboratories, AstraZeneca PLC, Walvax Biotechnology Co., Ltd., Bio-Manguinhos, Valneva SE, Sanofi S.A., and Biological E Limited.

Market Segmentation & Coverage

This research report categorizes the Travel Vaccines Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Attenuated Vaccines, Conjugate Vaccines, DNA Vaccines, Inactive Vaccines, Recombinant Vector Vaccines, Subunit Vaccines, and Toxoid Vaccines.
  • Based on Disease, market is studied across DPT, Hepatitis A, Hepatitis B, Japanese Encephalitis, Measles and Mumps, Meningococcal, Rabies, Typhoid, Varicella, and Yellow Fever.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing Popularity of International Tourism
      • 5.1.1.2. Growing Prevalence of Infectious Diseases and Development of Combination Vaccines
      • 5.1.1.3. Recent Investments and Improvement in Cold Chain Storage Infrastructure
    • 5.1.2. Restraints
      • 5.1.2.1. Limited Awareness Amongst Travelers
    • 5.1.3. Opportunities
      • 5.1.3.1. Innovations in Novel Vaccine Technologies and Advancements
      • 5.1.3.2. Government and Organizational Funding and Initiatives for Immunization and Vaccine Development
    • 5.1.4. Challenges
      • 5.1.4.1. Issues Related to Vaccine Handling and Storage
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Advancements in DNA vaccines to induce immune response
    • 5.2.2. Disease: Need based preference for hepatitis vaccines among travelers
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental
  • 5.5. Client Customization

6. Travel Vaccines Market, by Type

  • 6.1. Introduction
  • 6.2. Attenuated Vaccines
  • 6.3. Conjugate Vaccines
  • 6.4. DNA Vaccines
  • 6.5. Inactive Vaccines
  • 6.6. Recombinant Vector Vaccines
  • 6.7. Subunit Vaccines
  • 6.8. Toxoid Vaccines

7. Travel Vaccines Market, by Disease

  • 7.1. Introduction
  • 7.2. DPT
  • 7.3. Hepatitis A
  • 7.4. Hepatitis B
  • 7.5. Japanese Encephalitis
  • 7.6. Measles and Mumps
  • 7.7. Meningococcal
  • 7.8. Rabies
  • 7.9. Typhoid
  • 7.10. Varicella
  • 7.11. Yellow Fever

8. Americas Travel Vaccines Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Travel Vaccines Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Travel Vaccines Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
    • 11.3.1. India's First Indigenously Developed Hepatitis A Vaccine Launched In Hyderabad
    • 11.3.2. FDA Approves PENBRAYA, the First and Only Vaccine for the Prevention of the Five Most Common Serogroups Causing Meningococcal Disease in Adolescents
    • 11.3.3. Pfizer and BioNTech Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

Companies Mentioned

  • 1. Merck & Co., Inc.
  • 2. Takeda Pharmaceutical Company Limited
  • 3. Cadila Pharmaceuticals Limited
  • 4. Shenzhen Kangtai Biological Products Co., Ltd.
  • 5. Novartis AG
  • 6. Dynavax Technologies Corporation
  • 7. CSL Limited
  • 8. Emergent BioSolutions Inc.
  • 9. Bio-Med (P) Limited
  • 10. Bharat Biotech Ltd.
  • 11. Indian Immunologicals Ltd.
  • 12. Dano Vaccines & Biologicals Private Limited
  • 13. Bavarian Nordic A/S
  • 14. Johnson & Johnson Services, Inc
  • 15. Pfizer Inc.
  • 16. Incepta Pharmaceuticals Ltd.
  • 17. GlaxoSmithKline PLC
  • 18. Serum Institute of India Pvt. Ltd.
  • 19. Abbott Laboratories
  • 20. AstraZeneca PLC
  • 21. Walvax Biotechnology Co., Ltd.
  • 22. Bio-Manguinhos
  • 23. Valneva SE
  • 24. Sanofi S.A.
  • 25. Biological E Limited

LIST OF FIGURES

  • FIGURE 1. TRAVEL VACCINES MARKET RESEARCH PROCESS
  • FIGURE 2. TRAVEL VACCINES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. TRAVEL VACCINES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL TRAVEL VACCINES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL TRAVEL VACCINES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. TRAVEL VACCINES MARKET DYNAMICS
  • TABLE 7. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL TRAVEL VACCINES MARKET SIZE, BY ATTENUATED VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL TRAVEL VACCINES MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DNA VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL TRAVEL VACCINES MARKET SIZE, BY INACTIVE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RECOMBINANT VECTOR VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL TRAVEL VACCINES MARKET SIZE, BY SUBUNIT VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TOXOID VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL TRAVEL VACCINES MARKET SIZE, BY DPT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS A, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL TRAVEL VACCINES MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL TRAVEL VACCINES MARKET SIZE, BY JAPANESE ENCEPHALITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MEASLES AND MUMPS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL TRAVEL VACCINES MARKET SIZE, BY MENINGOCOCCAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL TRAVEL VACCINES MARKET SIZE, BY RABIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL TRAVEL VACCINES MARKET SIZE, BY TYPHOID, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL TRAVEL VACCINES MARKET SIZE, BY VARICELLA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL TRAVEL VACCINES MARKET SIZE, BY YELLOW FEVER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 28. AMERICAS TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES TRAVEL VACCINES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 40. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 43. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. AUSTRALIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 45. CHINA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. CHINA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. INDIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 53. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 55. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. PHILIPPINES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 57. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. SINGAPORE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 59. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. SOUTH KOREA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 61. TAIWAN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. TAIWAN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 63. THAILAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. THAILAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 65. VIETNAM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. VIETNAM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 69. EUROPE, MIDDLE EAST & AFRICA TRAVEL VACCINES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. DENMARK TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. DENMARK TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 72. EGYPT TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. EGYPT TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 74. FINLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. FINLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 76. FRANCE TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. FRANCE TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 78. GERMANY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. GERMANY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 80. ISRAEL TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. ISRAEL TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 82. ITALY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ITALY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 84. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. NETHERLANDS TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 86. NIGERIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 87. NIGERIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 88. NORWAY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. NORWAY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 90. POLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. POLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 92. QATAR TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. QATAR TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 94. RUSSIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. RUSSIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 96. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. SAUDI ARABIA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 98. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 99. SOUTH AFRICA TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 100. SPAIN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. SPAIN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 102. SWEDEN TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 103. SWEDEN TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 104. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 105. SWITZERLAND TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 106. TURKEY TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. TURKEY TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 108. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. UNITED ARAB EMIRATES TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 110. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. UNITED KINGDOM TRAVEL VACCINES MARKET SIZE, BY DISEASE, 2018-2030 (USD MILLION)
  • TABLE 112. TRAVEL VACCINES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 113. TRAVEL VACCINES MARKET, FPNV POSITIONING MATRIX, 2023